Skip to main content
. 2019 Nov;7(22):671. doi: 10.21037/atm.2019.10.33

Table 1. Clinicopathologic demographics of included patients before and after Propensity Score Matching.

Variables Before PSM After PSM
Total (N=803) Non-TD (N=666) TD (N=137) P value Total (N=411) Non-TD (N=274) TD (N=137) P value
Gender, n (%) 0.819 0.626
   Male 543 (67.6) 452 (67.9) 91 (66.4) 281 (68.3) 190 (69.3) 91 (66.4)
   Female 260 (32.4) 214 (32.1) 46 (33.6) 130 (31.7) 84 (30.7) 46 (33.6)
Age, median (IQR) 57 [49–66] 57 [50–66] 58 [48–68] 0.811 59 [49–68] 59 [49–67] 58 [48–68] 0.660
Tumor location, n (%) 0.414 0.361
   Lower 363 (45.2) 299 (44.9) 64 (46.7) 185 (45.0) 121 (44.2) 64 (46.7)
   Middle 199 (24.8) 161 (24.2) 38 (27.7) 103 (25.1) 65 (23.7) 38 (27.7)
   Upper 241 (30.0) 206 (30.9) 35 (25.6) 123 (29.9) 88 (32.1) 35 (25.6)
Differentiated degree, n (%) <0.001 0.268
   High 512 (63.7) 464 (69.7) 48 (35.0) 161 (39.2) 113 (41.2) 48 (35.0)
   Low 291 (36.3) 202 (30.3) 89 (65.0) 250 (60.8) 161 (58.8) 89 (65.0)
pT stage, n (%) <0.001 0.163
   pT1 112 (13.9) 107 (16.0) 5 (3.6) 9 (2.1) 4 (1.5) 5 (3.6)
   pT2 100 (12.5) 85 (12.8) 15 (10.9) 41 (10.0) 26 (9.5) 15 (10.9)
   pT3 187 (23.3) 164 (24.6) 23 (16.8) 82 (20.0) 59 (21.5) 23 (16.8)
   pT4a 294 (36.6) 233 (35.0) 61 (44.5) 200 (48.7) 139 (50.7) 61 (44.5)
   pT4b 110 (13.7) 77 (11.6) 33 (24.1) 79 (19.2) 46 (16.8) 33 (24.2)
pN stage, n (%) <0.001 0.371
   pN0 310 (38.6) 294 (44.1) 16 (11.7) 53 (12.9) 37 (13.5) 16 (11.7)
   pN1 143 (17.8) 132 (19.8) 11 (8.0) 34 (8.3) 23 (8.4) 11 (8.0)
   pN2 147 (18.3) 106 (15.9) 41 (29.9) 135 (32.8) 94 (34.3) 41 (29.9)
   pN3a 115 (14.3) 83 (12.5) 32 (23.4) 102 (24.8) 70 (25.5) 32 (23.4)
   pN3b 88 (11.0) 51 (7.7) 37 (27.0) 87 (21.2) 50 (18.3) 37 (27.0)
Chemotherapy, n (%) 0.712 0.093
   Yes 484 (60.3) 399 (59.9) 85 (62.0) 279 (67.9) 194 (70.8) 85 (62.0)
   No 319 (39.7) 267 (40.1) 52 (38.0) 132 (32.1) 80 (29.2) 52 (38.0)
Tumor size, n (%) <0.001 0.343
   <5 cm 451 (56.2) 395 (59.3) 56 (40.9) 183 (44.5) 127 (46.4) 56 (40.9)
   ≥5 cm 352 (43.8) 271 (40.7) 81 (59.1) 228 (55.5) 147 (53.6) 81 (59.1)

TD, tumor deposit; PSM, propensity score matching; IQR, interquartile range.